Nuclea wraps up $3.4 million funding

By Mass High Tech staff

Video Gallery

MHT's Julie Donnelly: Life science startups finding investments

Following the Clean Energy Council Fellows

MHT's Efrain Viscarolasaga: Tech companies may have to wait for stimulus funds

Spin Transfer whips up $36M in first round [February 13, 2012]

Oxford Immunotec taps Altieri as CFO [February 13, 2012]

SeraCare selling to Linden for $82M [February 13, 2012]

UtiliData finds more funding from Braemer [February 13, 2012]

Nuclea Bioechnologies, based in Pittsfield and Worcester, closed out a $3.4 million equity deal originally announced in June with an investment by New York-based Private Equity Investors Inc., according to a filing with the U.S. Securities and Exchange Commission.

Founded in Pittsfield and with operations on the Clark University campus in Worcester, Nuclea is involved in biomarker research focused on cancer. The university is one of the company’s collaborators. Nuclea CEO Patrick J. Muraca is an alumnus of the school, according to the company. The company changed its name from Nuclea Biomarkers LLC a year ago when it announced that it was moving operations to Worcester.

In June , the company filed an SEC notice saying that it had raised $1 million of a planned $3 million round without identifying the eight investors. In the latest amendment, dated Wednesday, the company listed Private Equity Investors venture partner Richard Vietor as a director. Vietor also serves on the boards of biopharmaceutical company QLT Inc. of Vancouver, B.C., and pediatric drugs company InfaCare Pharmaceutical Corp. of Pennsylvania.

Muraca couldn’t be reached for comment.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.